Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,046 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
Brandt A, Schultheiss C, Klinghammer K, Schafhausen P, Busch CJ, Blaurock M, Hinke A, Tometten M, Dietz A, Müller-Richter U, Hahn D, Alt J, Stein A, Binder M. Brandt A, et al. Among authors: stein a. Front Oncol. 2024 Feb 7;14:1283266. doi: 10.3389/fonc.2024.1283266. eCollection 2024. Front Oncol. 2024. PMID: 38384801 Free PMC article.
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D. Stein A, et al. Acta Oncol. 2015 Feb;54(2):171-8. doi: 10.3109/0284186X.2014.961649. Epub 2014 Oct 13. Acta Oncol. 2015. PMID: 25307517
T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, Asemissen AM, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M. Akyüz N, et al. Among authors: stein a. Int J Cancer. 2017 Jun 1;140(11):2535-2544. doi: 10.1002/ijc.30549. Epub 2017 Mar 6. Int J Cancer. 2017. PMID: 27925177
AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.
Kripp M, Prasnikar N, Vehling-Kaiser U, Quidde J, Al-Batran SE, Stein A, Neben K, Hannig CV, Tessen HW, Trarbach T, Hinke A, Hofheinz RD. Kripp M, et al. Among authors: stein a. Oncotarget. 2017 Sep 23;8(62):105061-105071. doi: 10.18632/oncotarget.21249. eCollection 2017 Dec 1. Oncotarget. 2017. PMID: 29285233 Free PMC article.
Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling.
Tintelnot J, Metz S, Trentmann M, Oberle A, von Wenserski L, Schultheiß C, Braig F, Kriegs M, Fehse B, Riecken K, Bokemeyer C, Stein A, Binder M. Tintelnot J, et al. Among authors: stein a. Front Oncol. 2020 Jan 21;9:1559. doi: 10.3389/fonc.2019.01559. eCollection 2019. Front Oncol. 2020. PMID: 32039027 Free PMC article.
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J, Goekkurt E, Binder M, Thuss-Patience P, Lorenzen S, Knorrenschild JR, Kretzschmar A, Ettrich T, Lindig U, Jacobasch L, Pink D, Al-Batran SE, Hinke A, Hegewisch-Becker S, Nilsson S, Bokemeyer C, Stein A. Tintelnot J, et al. Among authors: stein a. BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3. BMC Cancer. 2020. PMID: 32487035 Free PMC article.
3,046 results